| Literature DB >> 34021143 |
Kerstin Renner1, Tobias Schwittay1, Sophia Chaabane1, Johanna Gottschling1, Christine Müller1, Charlotte Tiefenböck1, Jan-Niklas Salewski1, Frederike Winter1,2, Simone Buchtler1, Saidou Balam1, Maximilian V Malfertheiner3, Matthias Lubnow3, Dirk Lunz4, Bernhard Graf4, Florian Hitzenbichler5, Frank Hanses5, Hendrik Poeck6, Marina Kreutz6, Evelyn Orsó7, Ralph Burkhardt7, Tanja Niedermair8,9, Christoph Brochhausen8,9, André Gessner10, Bernd Salzberger5, Matthias Mack11,12.
Abstract
Coronavirus disease 2019 (COVID-19) can lead to pneumonia and hyperinflammation. Here we show a sensitive method to measure polyclonal T cell activation by downstream effects on responder cells like basophils, plasmacytoid dendritic cells, monocytes and neutrophils in whole blood. We report a clear T cell hyporeactivity in hospitalized COVID-19 patients that is pronounced in ventilated patients, associated with prolonged virus persistence and reversible with clinical recovery. COVID-19-induced T cell hyporeactivity is T cell extrinsic and caused by plasma components, independent of occasional immunosuppressive medication of the patients. Monocytes respond stronger in males than females and IL-2 partially restores T cell activation. Downstream markers of T cell hyporeactivity are also visible in fresh blood samples of ventilated patients. Based on our data we developed a score to predict fatal outcomes and identify patients that may benefit from strategies to overcome T cell hyporeactivity.Entities:
Mesh:
Year: 2021 PMID: 34021143 DOI: 10.1038/s41467-021-23334-2
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919